Integrated single-cell and Mendelian randomization analyses: dissecting underlying causes of varied efficacy in immune neoadjuvant therapy for esophageal carcinoma.

IF 2.9 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Discover. Oncology Pub Date : 2025-10-16 DOI:10.1007/s12672-025-03751-1

Jiaxin Li, Sibo Meng, Ying Zhou, Yufeng Cheng

{"title":"Integrated single-cell and Mendelian randomization analyses: dissecting underlying causes of varied efficacy in immune neoadjuvant therapy for esophageal carcinoma.","authors":"Jiaxin Li, Sibo Meng, Ying Zhou, Yufeng Cheng","doi":"10.1007/s12672-025-03751-1","DOIUrl":null,"url":null,"abstract":"Background: Esophageal cancer has a low 5-year survival rate despite treatments. scRNA-seq and MR offer insights into neoadjuvant treatment efficacy for precision medicine.Methods: Three post-neoadjuvant treatment datasets underwent QC for Seurat analysis. Marker genes identified cell subsets. MR analyzed eQTL data from GWAS cohorts for causal links. Single-cell and MR-derived genes intersected to reveal PLTP in CD4⁺T cells.Results: Single-cell analysis of 16 samples found 40,198 genes and 120,102 cells. CD4⁺T cell numbers differed significantly between groups after therapy. Differentially expressed genes were immune-related. Pseudotime and cell-cell communication varied. PLTP, linked to esophageal cancer, co-expressed with genes involved in cell cycle processes.Conclusion: The study highlights CD4⁺T cells' predictive role in therapy efficacy via scRNA-seq and MR. PLTP emerges as a key gene, offering new precision medicine strategies for esophageal cancer.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1904"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12532960/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-03751-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Esophageal cancer has a low 5-year survival rate despite treatments. scRNA-seq and MR offer insights into neoadjuvant treatment efficacy for precision medicine.

Methods: Three post-neoadjuvant treatment datasets underwent QC for Seurat analysis. Marker genes identified cell subsets. MR analyzed eQTL data from GWAS cohorts for causal links. Single-cell and MR-derived genes intersected to reveal PLTP in CD4⁺T cells.

Results: Single-cell analysis of 16 samples found 40,198 genes and 120,102 cells. CD4⁺T cell numbers differed significantly between groups after therapy. Differentially expressed genes were immune-related. Pseudotime and cell-cell communication varied. PLTP, linked to esophageal cancer, co-expressed with genes involved in cell cycle processes.

Conclusion: The study highlights CD4⁺T cells' predictive role in therapy efficacy via scRNA-seq and MR. PLTP emerges as a key gene, offering new precision medicine strategies for esophageal cancer.

查看原文本刊更多论文

综合单细胞和孟德尔随机化分析：剖析食管癌免疫新辅助治疗不同疗效的潜在原因。

背景：食管癌治疗后5年生存率低。scRNA-seq和MR为精准医学的新辅助治疗效果提供了见解。方法：对三个新辅助治疗后的数据集进行QC进行Seurat分析。标记基因鉴定细胞亚群。MR分析了来自GWAS队列的eQTL数据以寻找因果关系。单细胞和mr衍生的基因相交，揭示了CD4 + T细胞中的PLTP。结果：对16份样本进行单细胞分析，发现40,198个基因和120,102个细胞。治疗后CD4 + T细胞数组间差异有统计学意义。差异表达基因与免疫相关。假时间和细胞-细胞通讯发生变化。与食管癌相关的PLTP与参与细胞周期过程的基因共表达。结论：本研究通过scRNA-seq机制，突出了CD4 + T细胞在治疗疗效中的预测作用，MR. PLTP作为关键基因出现，为食管癌的精准治疗提供了新的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊